Mural oncology plc MURA.US Overview
MURA AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
MURA Current Performance
-1.24%
Mural oncology plc
-2.38%
Avg of Sector
-0.30%
S&P500
MURA Key Information
MURA Revenue by Segments
Browsing restrictions can be lifted for a fee.
MURA Net Income
Browsing restrictions can be lifted for a fee.
MURA Cash Flow
Browsing restrictions can be lifted for a fee.
MURA Profit Margin
Browsing restrictions can be lifted for a fee.
MURA PE Ratio River
Browsing restrictions can be lifted for a fee.
MURA Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
MURA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
MURA Profile
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Price of MURA
MURA FAQ
When is MURA's latest earnings report released?
The most recent financial report for Mural oncology plc (MURA) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MURA's short-term business performance and financial health. For the latest updates on MURA's earnings releases, visit this page regularly.
How much debt does MURA have?
As of the end of the reporting period, Mural oncology plc (MURA) had total debt of 6.78M, with a debt ratio of 0.05. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does MURA have?
At the end of the period, Mural oncology plc (MURA) held Total Cash and Cash Equivalents of 108.65M, accounting for 0.82 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is MURA's EPS continuing to grow?
According to the past four quarterly reports, Mural oncology plc (MURA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.93. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of MURA?
Mural oncology plc (MURA)'s Free Cash Flow (FCF) for the period is -36.81M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 1.56% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.